Eleven drug classes are available as initial monotherapy for type 2 diabetes, presenting a vast choice in terms of therapeutic mechanism, adverse effect profile, efficacy, and cost. In 2012 in the United States, 18 million people filled 121 million prescriptions for these agents, and prescribing rates have increased rapidly—nearly 50% in 9 years.1 Given the prevalence of type 2 diabetes, identifying the optimal initial oral therapy is of national health policy importance.
Stern RJ, Murphy EJ. Metformin as Initial Oral Therapy in Type 2 Diabetes. JAMA. 2015;313(24):2484-2485. doi:10.1001/jama.2015.2765